Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Brensocatib 10 mg
DRUG
2 trials
Sponsors
Insmed Incorporated
Conditions
Non-Cystic Fibrosis Bronchiectasis
Phase 2
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
Completed
NCT03218917
Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
Start: 2017-10-31
End: 2019-12-12
Updated: 2023-03-27
Phase 3
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Completed
NCT04594369
Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
Start: 2020-12-01
End: 2024-10-28
Updated: 2025-12-16
Related Papers
Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial
Pulmonary Therapy
2026-07-16
Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial.
2026-01-09
Efficacy of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis With vs Without Maintenance Use of Macrolides: An Analysis of the ASPEN Trial
American Journal of Respiratory and Critical Care Medicine
2025-05-01
1 citations
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
New England Journal of Medicine
2025-04-23
69 citations
Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial
American Journal of Respiratory and Critical Care Medicine
2025-02-12
8 citations
The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration
British Journal of Clinical Pharmacology
2024-11-22
3 citations
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study
European Respiratory Journal
2024-09-10
47 citations
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics
ERJ Open Research
2024-04-25
31 citations
P111 Dipeptidyl peptidase-1 inhibition in bronchiectasis with eosinophilic endotype in the WILLOW trial
2023-11-01
3 citations
P112 Efficacy and safety of Dipeptidyl Peptidase-1 (DPP-1) inhibition in long-term macrolide users with bronchiectasis: a post-hoc analysis of the WILLOW trial
2023-11-01
2 citations
Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis
JDR Clinical & Translational Research
2023-09-25
2 citations
Pharmacokinetics and safety of brensocatib in patients with cystic fibrosis
2023-09-09
4 citations
Dipeptidyl peptidase-1 inhibition in bronchiectasis with eosinophilic endotype in the WILLOW trial
2023-09-09
1 citations
Treatment with the dipeptidyl peptidase-1 inhibitor brensocatib increases the antimicrobial peptide secretory leukocyte peptidase inhibitor (SLPI) in patients with bronchiectasis: results from the WILLOW trial
2023-09-09
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species
Frontiers in Pharmacology
2023-07-19
10 citations
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
Respiratory Research
2023-05-17
55 citations
A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf
ERJ Open Research
2023-05-01
35 citations
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
2022-07-25
19 citations
Bronchiectasis enters the inflammation era
Respirology
2022-04-13
11 citations
Exposure-response relationships of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
2021-09-05
2 more papers not shown